Alopexx, Inc. (ALPX)

Chart not available yet

Data will show when the stock starts trading on Feb 15, 2023.

Market Cap	39.26M
Revenue (ttm)	n/a
Net Income (ttm)	-956,954
Shares Out	7.85M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ALPX

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow t...

• Industry: Health Care
• Sector: Biotechnology
• IPO Date: Feb 15, 2023
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: ALPX